Article content
GREENWICH, Conn. — Soleus Capital Management, L.P. (“Soleus Capital”), a healthcare investment firm which owns in excess of 10% of the stock of Theratechnologies Inc. (NASDAQ: THTX) (the “Company”), today sent a letter to the Board of Directors of the Company.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
Exclusive articles from Barbara Shecter, Joe O’Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world’s leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
Exclusive articles from Barbara Shecter, Joe O’Connor, Gabriel Friedman and others.Daily content from Financial Times, the world’s leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an Accountor
Article content
Article content
In its letter, Soleus Capital described its belief that an acquisition of the Company is in the best interest of the Company’s shareholders and urged the Board to pursue an acquisition offer announced earlier today by Future Pak, LLC at a price of at least $3.51 per share, representing a premium of at least 163% to the closing price of the Company on April 10th.
Article content
Article content
The letter also described Soleus Capital’s concern that management of the Company and the Board had repeatedly ignored and/or been unresponsive to potential interested parties who have reached out to Company management for the purpose of entering into acquisition talks, which is inconsistent with management’s and the Board’s obligations to shareholders.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
Soleus stated that, given the significant premium and all-cash nature of the Future Pak offer, significantly more value would accrue to shareholders by accepting the offer rather than continuing as a standalone company or in any potential alternative combination which prioritizes management job preservation over shareholder value.
Article content
The full letter is available via this link: Letter to The Board
Article content
About Soleus Capital
Article content
Soleus Capital is a healthcare investment firm located in Greenwich, CT which manages hedge, private equity and credit funds primarily focused on the innovative areas of life sciences, including biotech, medtech, diagnostics, and genomics.
Article content
Disclaimer
Article content
The views expressed in this letter represent the opinions of Soleus Capital and are based on publicly available information with respect to the Company. Soleus Capital reserves the right to change any of its opinions expressed herein at any time as it deems appropriate and disclaims any obligation to notify the market or any other party of such change. Soleus Capital disclaims any obligation to update the information or opinions contained in the linked letter.
Article content
This letter is provided merely as information and is not intended to be, nor should it be construed as investment advice, or as an offer to sell or a solicitation of an offer to buy any security. This letter does not recommend the purchase or sale of any security. Soleus Capital currently beneficially owns shares of the Company. Soleus Capital is in the business of trading – buying and selling– securities and intends to continue trading in the securities of the Company. You should assume Soleus Capital will from time to time sell all or a portion of its holdings of the Company in open market transactions or otherwise, buy additional shares (in open market or privately negotiated transactions or otherwise), or trade in options, puts, calls, swaps or other derivative instruments relating to such shares.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Media Contact:
Anna Lowden
Anna@soleuscapital.com
Article content
Article content